Conjugated monoclonal antibodies and their role against cancer
1 Pharmacy student, Faculty of Pharmacy, Universidad de Costa Rica, San José, Costa Rica.
2 Industrial Pharmacy Department, Faculty of Pharmacy, Universidad de Costa Rica, San José, Costa Rica.
3 Instituto de Investigaciones Farmacéuticas (INIFAR), Faculty of Pharmacy, Universidad de Costa Rica, San José, Costa Rica.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(03), 029–044.
Article DOI: 10.30574/wjbphs.2024.19.3.0532
Publication history:
Received on 10 June 2024; revised on 25 June 2024; accepted on 21 August 2024
Abstract:
Cancer involves the proliferation of abnormal cells at an accelerated rate, which can have metastatic and invasive qualities. This illness is a significant public health problem worldwide. Usual treatments are surgery, radiotherapy, and chemotherapy. The drawback of these strategies is their adverse effects, which is why more specific options have been sought. Conjugated monoclonal antibodies have been manufactured to achieve this goal. Their structure comprises a monoclonal antibody, a cytotoxic agent or payload, and a linker, which holds the first two components together. Thanks to this technology, novel medications have yielded better results than traditional therapies. Through these findings, 11 drugs in this therapeutic category are being marketed worldwide. As a complement, significant advances in treating this pathology have led to continued research. In the short term, more conjugated monoclonal antibodies are expected to be approved by health authorities such as the United States Food and Drug Administration and the European Medicines Agency.
Keywords:
Cancer; Biological Drug; Monoclonal Antibody; Linker; Payload.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0